Cargando…
Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study
BACKGROUND: The long-term continuation of the low-dose antithyroid drug (ATD) beyond the standard duration of ATD therapy of 12–18 months to prevent recurrent hyperthyroidism (RH) is recommended with low quality of evidence. OBJECTIVES: To examine whether long-term continuation of low-dose ATD beyon...
Autores principales: | Lertwattanarak, Raweewan, Kunavisarut, Tada, Sriussadaporn, Sutin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578883/ https://www.ncbi.nlm.nih.gov/pubmed/36267362 http://dx.doi.org/10.1155/2022/1705740 |
Ejemplares similares
-
Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study
por: Sriussadaporn, Sutin, et al.
Publicado: (2017) -
Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea
por: Kunavisarut, Tada, et al.
Publicado: (2019) -
Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial
por: Azizi, Fereidoun, et al.
Publicado: (2021) -
Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report
por: Azizi, Fereidoun, et al.
Publicado: (2021) -
Long-term methimazole therapy in Graves’ hyperthyroidism and adverse reactions: a Danish multicenter study
por: Karmisholt, J, et al.
Publicado: (2022)